Evidence outlook
Approved: Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
109 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 102 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ustekinumab-Hmny (Starjemza): this drug | Approved | — | IL-12 p40 | ||
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | ||
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Aekn (Selarsdi) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Auub (Wezlana) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Srlf (Imuldosa) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Stba (Steqeyma) | Approved | — | IL-23 p19, IL-12 p40 | ||
| Ustekinumab-Ttwe (Pyzchiva) | Approved | — | IL-23 p19, IL-12 p40 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha |
…and 94 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.